3 news items
Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting
ZNTL
23 May 24
progression or death at 18 weeks compared with historical control patients. These results support studying the combination in patients facing this aggressive
Zentalis Pharmaceuticals To Highlight Preclinical Data Demonstrating That WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-Tumor Activity With KRAS(G12C) Inhibitors At AACR Annual Meeting 2024
ZNTL
2 Apr 24
by azenosertib suppresses key cell cycle checkpoints, preventing DNA repair and increasing DNA damage, resulting in mitotic catastrophe and cell death
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
ZNTL
2 Apr 24
DNA repair and increasing DNA damage, resulting in mitotic catastrophe and cell death. Previous research has determined that cancer cells, which
- Prev
- 1
- Next